Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Ironwood Pharmaceuticals (NASDAQ: IRWD) is a leading U.S. gastrointestinal (GI) healthcare company, dedicated to advancing the treatment of GI diseases and redefining the standard of care for GI patients. The company is focused on the development and commercialization of innovative medicines. Its flagship product, LINZESS® (linaclotide), is a U.S. market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Ironwood is also advancing a pipeline of innovative assets in areas of high unmet medical need within GI.
The Boston headquarters is the nerve center for Ironwood's operations, housing its executive leadership, strategic planning, research and development oversight, commercial strategy, corporate development, and core administrative functions.
The headquarters is located in a modern office building in downtown Boston, providing employees with state-of-the-art facilities and convenient access to the city's rich life sciences ecosystem and transportation networks.
Ironwood cultivates a patient-centric, science-driven, and collaborative work environment. The culture emphasizes innovation, agility, integrity, and a shared commitment to improving the lives of individuals suffering from GI disorders.
The Boston location provides strategic advantages, including access to a deep talent pool, proximity to world-class academic and research institutions, and a vibrant community of life science companies and investors.
While Ironwood Pharmaceuticals' direct commercial operations are focused on the United States, its lead product LINZESS® (linaclotide) has a global reach through strategic partnerships. AbbVie commercializes linaclotide as Constella® in Europe, Canada, and other markets. Astellas Pharma markets LINZESS® in Japan. Ironwood earns royalties from these ex-U.S. sales, extending the impact of its innovation to patients worldwide and supporting its ongoing research and development efforts.
100 Summer Street, Suite 2300
Boston
Massachusetts
USA
Address: N/A (Remote/Field-based)
These field teams are responsible for educating healthcare professionals about LINZESS®, supporting patient access to treatments, gathering medical insights, and representing the company within various regions of the U.S.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Ironwood Pharmaceuticals' leadership includes:
Ironwood Pharmaceuticals has been backed by several prominent investors over the years, including:
Over the past 12 months, Ironwood Pharmaceuticals has made key appointments to its executive leadership team, including a new Chief Financial Officer, Chief Legal Officer, and Chief People Officer, to support its strategic growth and focus on GI healthcare.
Discover the tools Ironwood Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
The most commonly observed email format for Ironwood Pharmaceuticals employees is the first initial of the first name followed by the full last name, then '@ironwoodpharma.com'. While other formats might exist internally, this is the predominant structure for external communications.
[first_initial][last]@ironwoodpharma.com
Format
jdoe@ironwoodpharma.com
Example
85%
Success rate
Business Wire • May 2, 2024
Ironwood Pharmaceuticals announced its first-quarter 2024 financial results, reporting total revenues of $107.1 million, driven by LINZESS U.S. net sales. The company reaffirmed its full-year 2024 financial guidance....more
Business Wire • March 18, 2024
Ironwood Pharmaceuticals announced the appointment of Rachael St. Clair as Chief People Officer, effective March 18, 2024. Ms. St. Clair will oversee all aspects of human resources and join the company's executive leadership team....more
Business Wire • February 15, 2024
Ironwood reported strong financial performance for Q4 and full-year 2023, with LINZESS U.S. net sales growing. The company also provided its outlook for 2024, emphasizing continued growth and pipeline advancement....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Ironwood Pharmaceuticals, are just a search away.